{"id":15630,"date":"2023-07-31T11:07:00","date_gmt":"2023-07-31T03:07:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15630"},"modified":"2024-11-29T11:11:00","modified_gmt":"2024-11-29T03:11:00","slug":"astrazenecas-h1-2023-financials-show-4-yoy-revenue-growth-oncology-and-ri-drive-sales","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15630","title":{"rendered":"AstraZeneca’s H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales"},"content":{"rendered":"\n

UK-based pharmaceutical giant AstraZeneca plc (AZ, NASDAQ: AZN<\/a>) has announced its financial results for the first half of 2023, marking another quarter of robust growth in both top-line and bottom-line figures. Global revenues for the six-month period increased by 4% year-on-year (YOY) in constant exchange rate terms to USD 22.295 billion.<\/p>\n\n\n\n

Excluding COVID-19 Sales Impact, Revenues Surge 16% YOY<\/strong>
When excluding the impact of COVID-19 sales, total revenues saw a significant increase of 16% YOY, with all non-COVID product divisions reporting double-digit growth. Oncology revenues jumped 22%, cardiovascular\/renal\/metabolic (CVRM) revenues increased by 20%, respiratory and immunology (R&I) grew at 10%, and Rare Diseases experienced a 12% YOY increase.<\/p>\n\n\n\n

Leading Products and Portfolio Performance<\/strong>
AstraZeneca boasted 8 products that generated over USD 1 billion in H1\u201923 sales. Oncology standouts included lung cancer treatment Tagrisso (osimertinib) with USD 2.9 billion in sales, up 12% YOY; PD-L1 inhibitor Imfinzi (durvalumab) with USD 1.97 billion, up 57% YOY; PARP inhibitor Lynparza (olaparib) with USD 1.37 billion, up 10%; and BTK inhibitor Calquence (acalabrutinib) with USD 1.18 billion, up 33%. In the CVRM portfolio, Farxiga (dapagliflozin) achieved USD 2.8 billion in sales, a 33% YOY growth. In R&I, Symbicort (budesonide, formoterol) grew sales by 4% YOY to USD 1.28 billion. Rare Disease portfolio saw Soliris (eculizumab) sales at USD 1.6 billion, a -16% YOY drop, while Ultomiris (ravolizumab) generated USD 1.36 billion, up 64%.<\/p>\n\n\n\n

China Market Forecast Upgraded<\/strong>
Regionally, excluding COVID sales, the US market grew by 17% to USD 4.782 billion, Emerging Markets including China rose by 19% to USD 3.115 billion, European sales increased by 18% to USD 2.2 billion, and the Rest of World region grew by 8% to USD 1.3 billion. China’s Q2\u201923 sales reached USD 1.44 billion with a 7% growth, leading AstraZeneca to raise its revenue growth forecast for the market to \u201clow to mid-single-digit percentage\u201d from the previously projected low single-digit.<\/p>\n\n\n\n

Addressing Portfolio Pressures and New Drug Approvals in China<\/strong>
During the earnings conference call, executive vice-president for international markets and China, Leon Wang, highlighted the mixed pressures on the current portfolio. Oncology drugs like Tagrisso saw volume-usage grow due to National Reimbursement Drug List (NRDL) entry, but sales values were impacted by price cuts during NRDL renegotiations. Several off-patent brands faced market sales adjustments due to volume-based procurement (VBP) tendering. New drug approvals are beginning to offset these pressures, as AstraZeneca aligns its China drug development with global standards. Q2\u201923 saw approvals for Enhertu (trastuzumab deruxtecan), Soliris (eculizumab), and Koselugo (selumetinib) in China, with expectations for additional approvals in 2024, including Beyfortus (nirsevimab) and Fasenra (benralizumab).<\/p>\n\n\n\n

CEO Pascal Soriot Dispels China-Spinoff Reports<\/strong>
CEO Pascal Soriot addressed recent media speculation about splitting off AstraZeneca’s China business, stating that such considerations are part of their strategic planning process, but the majority are not implemented. He confirmed satisfaction with the current structure in China.<\/p>\n\n\n\n

R&D Changes: New Leadership and Pipeline Adjustments<\/strong>
AstraZeneca also announced changes in its R&D leadership, with the retirement of Dr. Mene Pangalos and the appointment of Sharon Barr as the new head of R&D for biopharmaceuticals. Several new molecular entities were dropped from development, including the CDK9 inhibitor AZD4573 and three molecules at the Phase I stage.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

UK-based pharmaceutical giant AstraZeneca plc (AZ, NASDAQ: AZN) has announced its financial results for the…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[130,770,27,871],"class_list":["post-15630","post","type-post","status-publish","format-standard","hentry","category-company","tag-astrazeneca","tag-az","tag-finanical-reports","tag-nasdaq-azn"],"yoast_head":"\nAstraZeneca's H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based pharmaceutical giant AstraZeneca plc (AZ, NASDAQ: AZN) has announced its financial results for the first half of 2023, marking another quarter of robust growth in both top-line and bottom-line figures. Global revenues for the six-month period increased by 4% year-on-year (YOY) in constant exchange rate terms to USD 22.295 billion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15630\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca's H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15630\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-31T03:07:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-29T03:11:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15630#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15630\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca’s H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales\",\"datePublished\":\"2023-07-31T03:07:00+00:00\",\"dateModified\":\"2024-11-29T03:11:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15630\"},\"wordCount\":527,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraZeneca\",\"AZ\",\"Finanical Reports\",\"NASDAQ: AZN\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15630#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15630\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15630\",\"name\":\"AstraZeneca's H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-31T03:07:00+00:00\",\"dateModified\":\"2024-11-29T03:11:00+00:00\",\"description\":\"UK-based pharmaceutical giant AstraZeneca plc (AZ, NASDAQ: AZN) has announced its financial results for the first half of 2023, marking another quarter of robust growth in both top-line and bottom-line figures. Global revenues for the six-month period increased by 4% year-on-year (YOY) in constant exchange rate terms to USD 22.295 billion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15630#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15630\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15630#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca’s H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca's H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales - Insight, China's Pharmaceutical Industry","description":"UK-based pharmaceutical giant AstraZeneca plc (AZ, NASDAQ: AZN) has announced its financial results for the first half of 2023, marking another quarter of robust growth in both top-line and bottom-line figures. Global revenues for the six-month period increased by 4% year-on-year (YOY) in constant exchange rate terms to USD 22.295 billion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15630","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca's H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15630","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-31T03:07:00+00:00","article_modified_time":"2024-11-29T03:11:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15630#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15630"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca’s H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales","datePublished":"2023-07-31T03:07:00+00:00","dateModified":"2024-11-29T03:11:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15630"},"wordCount":527,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraZeneca","AZ","Finanical Reports","NASDAQ: AZN"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15630#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15630","url":"https:\/\/flcube.com\/?p=15630","name":"AstraZeneca's H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-31T03:07:00+00:00","dateModified":"2024-11-29T03:11:00+00:00","description":"UK-based pharmaceutical giant AstraZeneca plc (AZ, NASDAQ: AZN) has announced its financial results for the first half of 2023, marking another quarter of robust growth in both top-line and bottom-line figures. Global revenues for the six-month period increased by 4% year-on-year (YOY) in constant exchange rate terms to USD 22.295 billion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15630#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15630"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15630#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca’s H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15630","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15630"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15630\/revisions"}],"predecessor-version":[{"id":15631,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15630\/revisions\/15631"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15630"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15630"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15630"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}